PHIA Koninklijke Philips N.V.

Philips and World Stroke Organization partner to improve access to high-quality stroke care

Philips and World Stroke Organization partner to improve access to high-quality stroke care

October 10, 2023

  • Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge
  • Philips’ leadership in the rapid end-to-end treatment of stroke helping to improve patient outcomes and increase the efficiency of treatment

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the , the world’s only global non-governmental organization focused on stroke, today announced the signing of a two-year partnership aimed at improving access to high-quality stroke care. Building on their shared commitment to delivering improvements in stroke prevention, treatment, rehabilitation and support, Philips and WSO will leverage their respective strengths to elevate the public understanding of stroke as a global health issue, starting with joint initiatives on World Stroke Day 2023 (October 29) to build greater public awareness, which is fundamental to improving stroke patient outcomes. They will also work together to support the implementation of innovative treatment methods with the potential to transform the stroke care pathway, where reducing the time between symptom onset and effective treatment is critical to improving patient outcomes.

Announcing the partnership WSO President Prof Sheila Martins said, “WSO is committed to accelerating the global implementation of evidence-based treatment and care for stroke patients globally. We know what works and we know that it takes every part of the healthcare system, working together to bring quality care to every patient.”

“Both innovation and public awareness are essential to improve time-to-treatment and access to care for patients suffering a stroke,” said Dr. Atul Gupta, Chief Medical Officer of Image Guided Therapy at Philips. “Working closely with WSO, we can further shape the future of and help provide groundbreaking and effective high-quality care to patients so they can resume normal life after a stroke.”

Stroke is the second leading cause of death and the leading cause of disability worldwide, with around 12 million people experiencing a stroke each year, including 6.5 million people who die as a result. Those who do survive are often left with a complex range of communication, cognitive, physical, and emotional challenges for the rest of their life. To improve access to high-quality care that reduces the burden stroke places on individuals, and the financial and social impact it has on society, Philips and WSO will collaborate across a range of stroke-related areas. These include driving advocacy and policy based on the latest clinical research and treatment guidelines to inform government departments and healthcare providers about the latest developments in stroke treatment, and supporting community engagement.

Philips is a recognized leader in solutions that support the rapid treatment of stroke to minimize its impact on patients, including solutions for stroke monitoring and communication in ambulances, tele-stroke patient assessment, artificial intelligence (AI) supporting diagnostic imaging and analysis, image-guided therapy, and neurological and cardiac monitoring and assessment. The company also offers fully integrated angio suite systems designed to facilitate a stroke procedure called mechanical thrombectomy. During a thrombectomy, a specialized medical device is used to physically remove or break up the clot, restoring blood flow to the affected part of the brain. This quality-of-life-saving procedure is often performed to minimize damage to brain tissue and improve the chances of a patient's recovery after a stroke.

For further information, please contact:

Joost Maltha 

Philips Global Press Office 

Tel: +31 6 10 55 8116  

Email: 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment



EN
10/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch